Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 2/20 | 0.48 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.48 |
| ▸ | GAA | P10253 | 3/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | DGAT1 | O75907 | 2/20 | 0.42 |
| ▸ | BRD4 | O60885 | 3/20 | 0.42 |
| ▸ | SDHB | P21912 | 1/20 | 0.42 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.41 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | GALR3 | O60755 | 1/20 | 0.39 |
| ▸ | NPY1R | P25929 | 1/20 | 0.39 |
| ▸ | STAT3 | P40763 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7469586 | 0.90 | PTGS2 (0.46) | NR1H3GAAALDH1A1KDM4ELMNA | |
| SCHEMBL10177495 | 0.86 | SDHB (0.42) | DGAT1BRD4SDHBUSP1PTGS2 | |
| SCHEMBL16660862 | 0.86 | DGAT1 (0.58) | DGAT1BRD4SDHBUSP1PTGS2 | |
| SCHEMBL13100054 | 0.82 | PTGS2 (0.61) | SDHBPTGS2PTGS1 | |
| SCHEMBL24185774 | 0.81 | DGAT1 (0.49) | NR1H2NR1H3ALDH1A1KDM4EDGAT1 | |
| SCHEMBL24185626 | 0.80 | DGAT1 (0.45) | ALDH1A1KDM4EDGAT1PTGS2PTGS1 | |
| SCHEMBL29194233 | 0.78 | DRD2 (0.47) | ALDH1A1DGAT1SDHBMEN1KMT2A | |
| SCHEMBL24185640 | 0.78 | DGAT1 (0.46) | ALDH1A1KDM4EDGAT1PTGS2PTGS1 | |
| SCHEMBL24185707 | 0.78 | DGAT1 (0.52) | NR1H2NR1H3ALDH1A1KDM4EDGAT1 | |
| SCHEMBL13099659 | 0.77 | PTGS2 (0.60) | PTGS2PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9975871-B2 | Continuous arycyclic compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2018-05-22 | — | — | US | disclosed |
| US-9975871-B2 | Continuous arycyclic compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2018-05-22 | — | — | US | disclosed |
| US-20160272614-A1 | CONTINUOUS ARYCYCLIC COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2016-09-22 | — | — | US | disclosed |
| US-20160272614-A1 | CONTINUOUS ARYCYCLIC COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2016-09-22 | — | — | US | disclosed |
| US-20160272614-A1 | CONTINUOUS ARYCYCLIC COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2016-09-22 | — | — | US | disclosed |
| EP-2651915-B1 | CONTINUOUS ARYCYCLIC COMPOUND | MITSUBISHI TANABE PHARMA CORP (JP) | 2016-05-25 | — | — | EP | disclosed |
| EP-2651915-B1 | CONTINUOUS ARYCYCLIC COMPOUND | MITSUBISHI TANABE PHARMA CORP (JP) | 2016-05-25 | — | — | EP | disclosed |
| US-9302996-B2 | Continuous arycyclic compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2016-04-05 | — | — | US | disclosed |
| US-9302996-B2 | Continuous arycyclic compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2016-04-05 | — | — | US | disclosed |
| US-9302996-B2 | Continuous arycyclic compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2016-04-05 | — | — | US | disclosed |
| CN-103261185-B | Continuous arycyclic compound | MITSUBISHI TANABE PHARMA CORP | 2014-12-10 | — | — | CN | disclosed |
| EP-2651915-A1 | CONTINUOUS ARYCYCLIC COMPOUND | Mitsubishi Tanabe Pharma Corporation (JP) | 2013-10-23 | — | — | EP | disclosed |
| US-20130261128-A1 | CONTINUOUS ARYCYCLIC COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2013-10-03 | — | — | US | disclosed |
| US-20130261128-A1 | CONTINUOUS ARYCYCLIC COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2013-10-03 | — | — | US | disclosed |
| US-20130261128-A1 | CONTINUOUS ARYCYCLIC COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2013-10-03 | — | — | US | disclosed |
| CN-103261185-A | Continuous arycyclic compound | MITSUBISHI TANABE PHARMA CORP | 2013-08-21 | — | — | CN | disclosed |
| WO-2012081736-A1 | CONTINUOUS ARYCYCLIC COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-06-21 | — | — | WO | disclosed |
| WO-2012081736-A1 | CONTINUOUS ARYCYCLIC COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130261128-A1 | CONTINUOUS ARYCYCLIC COMPOUND | DGAT1, DGAT2, SOAT1 | NR1H2 104/4885NR1H3 131/4885GAA 715/4885 |
| US-20160272614-A1 | CONTINUOUS ARYCYCLIC COMPOUND | DGAT1, DGAT2, SOAT1 | NR1H2 104/4885NR1H3 131/4885GAA 715/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.